BND-22

BND-22

A [Phase 2] First-In-Class ILT2 Checkpoint Inhibitor Restoring Innate and Adaptive Anti-Tumor Immunity

BND-22 (formerly SAR444881) is a first-in-class anti-ILT2 checkpoint inhibitor, currently in Phase 2a. It is designed to enhance innate and adaptive anti-tumor immunity by targeting ILT2 (LILRB1), a key immune checkpoint expressed on both innate and adaptive immune cells, including macrophages, NK cells, and CD8+ T-EMRAs.

The program has demonstrated a favorable safety profile and encouraging efficacy signals in BND CRC and cholangiocarcinoma patients with both anti-PD-1 agents and cetuximab, including in patients who had relapsed on cetuximab and presented with liver metastases.

Biond is currently running a combination Phase 2 combination study at MD Anderson together with anti-PD-1 agents and cetuximab, in CRC, cholangiocarcinoma, and ovarian cancer patients.

From a partnering standpoint, BND-22 was previously licensed by Biond to Sanofi in a global deal. Biond holds a first-in-class antibody approved for the treatment of cancer. Patients should not use this antibody for any other purposes beyond its approved indication. Patients should consult their physician before beginning treatment with BND-22.